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F
etal alcohol syndrome (FAS) is 
the most common, nongenetic 
cause of mental retardation, 
and has a signiﬁ  cant national health 
impact [1]. Meeting the criteria for this 
condition requires the identiﬁ  cation of 
speciﬁ  c features, involving craniofacial 
dysmorphology (particularly midfacial 
anomalies), growth retardation, 
and deﬁ  cits in brain function. Most 
children with alcohol-induced 
prenatal deﬁ  cits do not have this full 
syndrome, but, instead, they fall under 
the umbrella term of fetal alcohol 
spectrum disorder (FASD). These 
disorders result from prenatal alcohol 
exposure, and the sequelae include 
speciﬁ  c neurodevelopmental and 
behavioral disorders. 
Recent reports suggest that fetal 
alcohol spectrum disorders affect 
one out of 100 children born in the 
United States [2]. There have been 
numerous public health approaches 
to alerting women to the dangers of 
drinking during pregnancy—including 
warning labels appearing on alcoholic 
beverages in 1989 (Box 1), and a US 
Surgeon General warning issued in 
1981 (updated and reissued in 2005) 
urging women who are pregnant 
or who may become pregnant to 
abstain from alcohol (http:⁄⁄www.hhs.
gov/surgeongeneral/pressreleases/
sg02222005.html). Yet despite these 
warnings, alcohol use during pregnancy 
is common, with up to 50% of women 
of childbearing age consuming alcohol, 
15%–20% acknowledging continuing 
to drink when pregnant, and one in 
25 pregnant women reporting binge 
drinking [3,4].
Can We Limit the Damage to the 
Fetus?
It is critically important to understand 
the role of alcohol’s effects during 
pregnancy for two main reasons. First, 
such knowledge will help to bolster 
public health warnings about drinking 
during pregnancy. Second, a better 
understanding of how alcohol causes 
fetal damage will help in developing 
preventive interventions to protect the 
fetus in situations where it is exposed to 
alcohol. 
Researchers have evaluated a 
number of therapies for the prevention 
of alcohol-induced damage in model 
systems. These therapies include 
neuroprotective peptides [5–7] and 
antioxidants targeting the prevention 
of ethanol-induced apoptosis [8,9]. 
And now Ieraci and Herrera report in 
PLoS Medicine that nicotinamide, a drug 
that has been used in humans to treat 
autoimmune diseases such as diabetes 
and bullous pemphigoid, protects 
against ethanol-induced apoptotic 
neurodegeneration in the developing 
mouse brain [10]. Their study provides 
a substantial contribution toward 
ﬁ  nding a treatment to prevent alcohol-
induced damage. 
Ieraci and Herrera treated seven-
day-old mice with 20% ethanol. 
The animals were also treated with 
nicotinamide at varying doses and time 
points; in each litter, animals were 
equally distributed into the different 
treatment groups. Cytochrome-
c release (which is released from 
mitochondria during oxygen–glucose 
deprivation) was evaluated using 
Western Blot in forebrain tissue. Blood 
and brain samples were tested at 
speciﬁ  c time points to quantify ethanol 
levels. To assess for neurodegeneration, 
Fluoro-Jade-B staining was performed 
histologically on perfused and 
sectioned brain slices. Behavioral tests 
were performed to evaluate for alcohol-
induced impairments. After weaning, 
offspring were tested using the open 
ﬁ  eld maze to assess spontaneous 
motor activity, the elevated plus maze 
to evaluate anxiety and activity, and 
the fear conditioning test to assess 
hippocampal learning and memory.
In their study, the authors 
evaluated the role of nicotinamide 
during ethanol exposure, focusing 
on the etiology of alcohol-induced 
microcephaly. Their work builds 
upon the known role of caspase-3 
activation in the forebrain, which 
triggers apoptotic neuronal death after 
ethanol exposure. The authors report 
that nicotinamide administration 
reduced the activation of caspase-3 
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Box 1. Warning Labels on 
Alcohol 
The Omnibus Drug Initiative Act 
of 1988 enacted by the US Congress 
required that all containers of alcoholic 
beverages produced for domestic 
consumption carry the following 
warning labels, effective November 
19, 1989: “l. According to the Surgeon 
General, women should not drink 
alcoholic beverages during pregnancy 
because of the risk of birth defects. 2. 
Consumption of alcoholic beverages 
impairs your ability to drive a car or 
operate machinery, and may cause health 
problems.”
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in the forebrain. It also prevented 
ethanol-induced neuronal death in 
speciﬁ  c brain regions and long-term 
behavioral disturbances in activity 
and learning. Ethanol-treated mice 
usually show increased activity, and 
nicotinamide prevented this alcohol-
induced increase in activity—as 
assessed by the number of times an 
animal crossed a horizontal line and 
reared onto two legs (i.e., assessment 
of both horizontal and vertical activity). 
In addition, nicotinamide prevented 
ethanol learning impairment in the 
fear-conditioning paradigm, where 
animals associate a context with a 
physical shock.
Strengths and Limitations of the 
Approach
As with all animal models, the 
limitations of Ieraci and Herrera’s 
work lie in translating the ﬁ  ndings 
to humans and in using the ﬁ  ndings 
to identify and optimize treatment 
strategies. Clearly, signiﬁ  cant work 
is needed to take the study ﬁ  ndings 
further. 
A simpler method for the prevention 
of alcohol-induced damage in 
pregnancy is obviously the cessation 
of alcohol consumption. However, 
given the widespread and apparently 
increasing fetal exposure to alcohol, it 
is unlikely that such cessation will occur 
in the ensuing decades. Therefore, 
research such as that by Ieraci and 
Herrera is essential to enhance 
our understanding and to develop 
therapeutic interventions. 
Ieraci and Herrera have elegantly 
evaluated one such intervention 
(nicotinamide) and have shown its 
impact at the molecular, cellular, and 
behavioral level. If it does turn out that 
nicotinamide is effective in preventing 
alcohol-induced fetal damage in 
human trials, a challenge will then be 
to determine when intervention with 
the treatment is possible. In this report, 
the intervention was given at varying 
time points after a single ﬁ  xed dose of 
ethanol. But giving any therapy during 
pregnancy is inherently difﬁ  cult, 
both for the potential other effects 
of the treatment on the developing 
embryo and for the implicit difﬁ  culties 
in identifying alcohol use during 
pregnancy. 
Clinical Implications
For clinicians and clinical researchers, 
this new study provides insights into 
the roles of caspase-3 and the release 
of cytochrome-c in alcohol-induced 
damage in the developing brain, and 
into the use of an interventional agent 
that targets this damage. This study and 
others suggest that there is potential 
that a therapy may be available in the 
future for preventing FAS and FASD. 
However, there are many hurdles to 
clear before such a therapy is available.
For a start, it is difﬁ  cult to identify 
the use of alcohol or other substances 
of abuse during pregnancy, as 
women themselves are unlikely to 
volunteer this information. And even 
if we can identify women who drink 
during pregnancy, there are many 
variables that could inﬂ  uence the 
success of an intervention to prevent 
FAS or FASD: (1) the wide range of 
ways in which pregnant women use 
alcohol (e.g., regular drinking, binge 
drinking, or just one-off drinking); 
(2) the continuously developing 
embryo’s different vulnerabilities 
to alcohol-induced damage (the 
impact of alcohol is different during 
organogenesis compared with that 
during second or third trimesters); 
(3) the woman’s genetic background; 
(4) the possibility of additive effects 
from other exposures (nicotine, 
environmental factors, other drugs); 
and (5) the possibility that the 
intervention itself turns out to be 
teratogenic. We still do not know how 
all these variables would affect the 
success of a therapeutic intervention 
given during pregnancy.
An alternative strategy would be 
to develop interventions that are 
administered once a developmental 
problem is identiﬁ  ed in the child, i.e., 
long after the initial alcohol exposure. 
For example, perhaps there may be 
value in giving nicotinamide or other 
therapies to a school-aged child with 
learning impairment due to FAS or 
FASD. Ultimately, this alternative 
strategy may end up being a more 
valuable one, as it targets children with 
known problems and avoids the risks of 
teratogenicity associated with giving a 
drug during pregnancy.  
References
1.  Stratton K, Howe C, Battaglia F (1996) Fetal 
alcohol syndrome: Diagnosis, epidemiology, 
prevention, and treatment. Washington (D. 
C.): National Academy Press. 213 p.
2.  Sampson PD, Streissguth AP, Bookstein GL, 
Little RE, Clarren SK, et al. (1997) Incidence 
of fetal alcohol syndrome and prevalence of 
alcohol-related neurodevelopmental disorder. 
Teratology 56: 317–326.
3.  Floyd RL, O’Connor MJ, Sokol RJ, Bertrand J, 
Cordero JF (2005) Recognition and prevention 
of fetal alcohol syndrome. Obstet Gynecol 106: 
1059–1064.
4.  Sokol RJ, Delaney-Black V, Nordstrom B (2003) 
Fetal alcohol spectrum disorder. JAMA 290: 
2996–2999.
5. Zhou FC, Sari Y, Powrozek TA, Spong CY (2004) 
A neuroprotective peptide antagonizes fetal 
alcohol exposure compromised brain growth. 
J Mol Neurosci 24: 189–199.
6.  Endres M, Toso L, Roberson R, Park J, 
Abebe D, et al. (2005) Prevention of alcohol-
induced developmental delays and learning 
abnormalities in a model of fetal alcohol 
syndrome. Am J Obstet Gynecol 193: 1028–
1034.
7.  Spong CY, Abebe DT, Gozes I, Brenneman DE, 
Hill JM (2001) Prevention of fetal demise and 
growth restriction in a mouse model of fetal 
alcohol syndrome. J Pharmacol Exp Ther 297: 
774–779.
8.  Kilburn BA, Chiang PJ, Wang J, Flentke GR, 
Smith SM, et al. (2006) Rapid induction of 
apoptosis in gastrulating mouse embryos by 
ethanol and its prevention by HB-EGF. Alcohol 
Clin Exp Res 30: 127–134.
9.  Heaton MB, Madorsky I, Paiva M, Siler-
Marsiglio KI (2004) Vitamin E amelioration 
of ethanol neurotoxicity involved modulation 
of apoptosis-related protein levels in neonatal 
rat cerebellar granule cells. Brain Res Dev 150: 
117–124.
10. Ieraci A, Herrera DG (2006) Nicotinamide 
protects against ethanol-induced apoptotic 
neurodegeneration in the developing mouse 
brain. PLoS Med 3: e101. DOI: 10.1371/
journal.pmed.0030101
April 2006  |  Volume 3  |  Issue 4  |  e196